Summary
Johnson & Johnson (JNJ) filed an 8-K on January 23, 2018, reporting its financial results for the fourth quarter and full year ended December 31, 2017. The filing primarily consists of a press release and supplementary sales data, providing investors with key financial performance metrics. This information is crucial for assessing the company's operational health, revenue generation, and profitability across its diverse business segments, including Pharmaceuticals, Medical Devices, and Consumer Health.
Key Highlights
- 1Johnson & Johnson announced its Q4 and full-year 2017 financial results on January 23, 2018.
- 2The 8-K filing includes the official press release detailing sales and earnings for the periods ended December 31, 2017.
- 3Investors can find unaudited comparative supplementary sales data and condensed consolidated statements of earnings within the filing.
- 4The reporting covers both the fourth quarter and the entirety of the fiscal year 2017.
- 5This report provides essential financial performance information for evaluating JNJ's operational and financial condition.